School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.
Department of Molecular and Integrative Physiology, University of Kansas Medical School, Kansas City, Kansas, USA.
J Clin Invest. 2018 Dec 3;128(12):5198-5200. doi: 10.1172/JCI124304. Epub 2018 Oct 22.
Obesity and overnutrition increase levels of reactive sugar- and lipid-derived aldehydes called reactive carbonyl species (RCS). Increased tissue and circulating RCS levels have been tied to insulin resistance and inflammation, but previous pharmacological approaches to target RCS have had equivocal outcomes. In this issue of the JCI, Anderson et al. present evidence for the development and implementation of carnisonol, a compound that is biologically stable in vivo and shows impressive effects on improving metabolism and inflammation in rodent models of diet-induced obesity and metabolic dysfunction.
肥胖和营养过剩会增加反应性糖和脂质衍生的醛类物质的水平,这些醛类物质被称为反应性羰基化合物(RCS)。组织和循环中的 RCS 水平升高与胰岛素抵抗和炎症有关,但以前针对 RCS 的药物治疗方法的结果并不明确。在本期 JCI 中,Anderson 等人提供了证据,证明了 carnisonol 的开发和应用,该化合物在体内具有生物稳定性,并在改善饮食诱导肥胖和代谢功能障碍的啮齿动物模型中的代谢和炎症方面具有显著效果。